Imaging-Based Characterization of a <i>Slco2b1<sup>(-/-)</sup></i> Mouse Model Using [<sup>11</sup>C]Erlotinib and [<sup>99m</sup>Tc]Mebrofenin as Probe Substrates

Organic anion-transporting polypeptide 2B1 (OATP2B1) is co-localized with OATP1B1 and OATP1B3 in the basolateral hepatocyte membrane, where it is thought to contribute to the hepatic uptake of drugs. We characterized a novel <i>Slco2b1<sup>(-/-)</sup></i> mouse model using po...

Full description

Saved in:
Bibliographic Details
Main Authors: Solène Marie (Author), Irene Hernández-Lozano (Author), Louise Breuil (Author), Charles Truillet (Author), Shuiying Hu (Author), Alex Sparreboom (Author), Nicolas Tournier (Author), Oliver Langer (Author)
Format: Book
Published: MDPI AG, 2021-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_cc05e363c9f947968ceae48fa5c99dcb
042 |a dc 
100 1 0 |a Solène Marie  |e author 
700 1 0 |a Irene Hernández-Lozano  |e author 
700 1 0 |a Louise Breuil  |e author 
700 1 0 |a Charles Truillet  |e author 
700 1 0 |a Shuiying Hu  |e author 
700 1 0 |a Alex Sparreboom  |e author 
700 1 0 |a Nicolas Tournier  |e author 
700 1 0 |a Oliver Langer  |e author 
245 0 0 |a Imaging-Based Characterization of a <i>Slco2b1<sup>(-/-)</sup></i> Mouse Model Using [<sup>11</sup>C]Erlotinib and [<sup>99m</sup>Tc]Mebrofenin as Probe Substrates 
260 |b MDPI AG,   |c 2021-06-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics13060918 
500 |a 1999-4923 
520 |a Organic anion-transporting polypeptide 2B1 (OATP2B1) is co-localized with OATP1B1 and OATP1B3 in the basolateral hepatocyte membrane, where it is thought to contribute to the hepatic uptake of drugs. We characterized a novel <i>Slco2b1<sup>(-/-)</sup></i> mouse model using positron emission tomography (PET) imaging with [<sup>11</sup>C]erlotinib (a putative OATP2B1-selective substrate) and planar scintigraphic imaging with [<sup>99m</sup>Tc]mebrofenin (an OATP1B1/1B3 substrate, which is not transported by OATP2B1). Dynamic 40-min scans were performed after intravenous injection of either [<sup>11</sup>C]erlotinib or [<sup>99m</sup>Tc]mebrofenin in wild-type and <i>Slco2b1<sup>(-/-)</sup></i> mice. A pharmacokinetic model was used to estimate the hepatic uptake clearance (CL<sub>1</sub>) and the rate constants for transfer of radioactivity from the liver to the blood (<i>k</i><sub>2</sub>) and excreted bile (<i>k</i><sub>3</sub>). CL<sub>1</sub> was significantly reduced in <i>Slco2b1<sup>(-/-)</sup></i> mice for both radiotracers (<i>p</i> < 0.05), and <i>k</i><sub>2</sub> was significantly lower (<i>p</i> < 0.01) in <i>Slco2b1<sup>(-/-)</sup></i> mice for [<sup>11</sup>C]erlotinib, but not for [<sup>99m</sup>Tc]mebrofenin. Our data support previous evidence that OATP transporters may contribute to the hepatic uptake of [<sup>11</sup>C]erlotinib. However, the decreased hepatic uptake of the OATP1B1/1B3 substrate [<sup>99m</sup>Tc]mebrofenin in <i>Slco2b1<sup>(-/-)</sup></i> mice questions the utility of this mouse model to assess the relative contribution of OATP2B1 to the liver uptake of drugs which are substrates of multiple OATPs. 
546 |a EN 
690 |a OATP2B1 
690 |a drug transporters 
690 |a [<sup>11</sup>C]erlotinib 
690 |a [<sup>99m</sup>Tc]mebrofenin 
690 |a liver 
690 |a imaging 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 13, Iss 6, p 918 (2021) 
787 0 |n https://www.mdpi.com/1999-4923/13/6/918 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/cc05e363c9f947968ceae48fa5c99dcb  |z Connect to this object online.